Galera Therapeutics Announces Avasopasem Manganese (GC4419) Maintained Anti-Cancer Benefit of Chemoradiotherapy for Head and Neck Cancer While Substantially Reducing Radiation-Induced Seve...
Galera Therapeutics, Inc. (GRTX)
Company Research
Source: GlobeNewswire
MALVERN, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced full tumor outcomes results from the two-year follow-up of patients with head and neck cancer treated with avasopasem manganese (GC4419), Galera’s lead product candidate for severe oral mucositis (SOM), in a Phase 2b clinical trial. The results will be presented February 28, 2020, during a late-breaking oral presentation at the 2020 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale, Ariz. “There is currently no drug to prevent or treat SOM, one of the most common and disruptive side effects of radiation therapy that severely impacts both a patient’s quality of life and treatment experience,” said Mel Sorensen, M.D., President and CEO of Galera Therapeutics. “Avasopasem mangan
Show less
Read more
Impact Snapshot
Event Time:
GRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GRTX alerts
High impacting Galera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GRTX
News
- Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates [Yahoo! Finance]Yahoo! Finance
- Galera Reports First Quarter 2024 Financial Results and Recent Corporate UpdatesGlobeNewswire
- Galera Adopts Limited Duration Stockholder Rights Agreement [Yahoo! Finance]Yahoo! Finance
- Galera Adopts Limited Duration Stockholder Rights AgreementGlobeNewswire
- Carisma Therapeutics names Eugene Kennedy as chief medical officer May 02, 2024 8:02 AM ET By: Sinchita Mitra , SA News Editor [Seeking Alpha]Seeking Alpha
GRTX
Sec Filings
- 5/16/24 - Form SC
- 5/16/24 - Form 3
- 5/16/24 - Form SC
- GRTX's page on the SEC website